[
  {
    "id": "L01_Q1",
    "stem": "Benzodiazepines exert their sedative-hypnotic effect at the GABAA receptor primarily by:",
    "options": [
      "Increasing the duration of chloride channel opening in the absence of GABA",
      "Increasing the frequency of GABA-dependent chloride channel opening",
      "Directly opening the chloride channel without GABA",
      "Increasing the number of GABAA receptors expressed on the cell surface"
    ],
    "correct_option_index": 1,
    "blooms_level": "Understand",
    "naplex_domain": "Pharmacology / Mechanism of Action",
    "acpe_outcomes": ["1.1"],
    "difficulty_target_p": 0.75,
    "discrimination_target_d": 0.3,
    "topic_tags": ["BZDs", "MOA", "GABAA"],
    "distractor_rationale": {
      "0": "Confuses BZD effect with barbiturates (duration vs frequency).",
      "2": "Assumes direct agonist action instead of allosteric modulation.",
      "3": "Reflects misunderstanding of acute modulation vs long-term receptor regulation."
    }
  },
  {
    "id": "L01_Q2",
    "stem": "The primary benzodiazepine binding site on the GABAA receptor is located at the interface between:",
    "options": [
      "β and γ subunits",
      "α and β subunits",
      "α and γ subunits",
      "Two α subunits"
    ],
    "correct_option_index": 2,
    "blooms_level": "Remember",
    "naplex_domain": "Pharmacology / Mechanism of Action",
    "acpe_outcomes": ["1.1"],
    "difficulty_target_p": 0.7,
    "discrimination_target_d": 0.3,
    "topic_tags": ["BZDs", "MOA", "ReceptorStructure"],
    "distractor_rationale": {
      "0": "Plausible but incorrect interface.",
      "1": "Confuses BZD site with GABA binding site.",
      "3": "Non-physiologic binding interface; tests receptor structure knowledge."
    }
  },
  {
    "id": "L01_Q3",
    "stem": "For classical benzodiazepines, the presence of which group at the C7 position on Ring A is most strongly associated with increased binding affinity and potency?",
    "options": [
      "Bulky tert-butyl group",
      "Alkyl chain without heteroatoms",
      "Electronegative substituent such as Cl or NO2",
      "Primary amine substituent"
    ],
    "correct_option_index": 2,
    "blooms_level": "Apply",
    "naplex_domain": "Structure–Activity Relationships (SAR)",
    "acpe_outcomes": ["1.1", "1.2"],
    "difficulty_target_p": 0.65,
    "discrimination_target_d": 0.35,
    "topic_tags": ["BZDs", "SAR", "RingA"],
    "distractor_rationale": {
      "0": "Tests misconception that bulk always improves potency.",
      "1": "Non-electronegative; does not provide classic C7 SAR benefit.",
      "3": "Would disrupt electronic environment and pharmacophore."
    }
  },
  {
    "id": "L01_Q4",
    "stem": "Introducing a 3-hydroxyl (3-OH) group into the benzodiazepine scaffold (as in temazepam) primarily affects pharmacokinetics by:",
    "options": [
      "Promoting direct glucuronidation and shortening half-life",
      "Preventing Phase II conjugation and prolonging half-life",
      "Increasing lipophilicity and CNS penetration",
      "Creating multiple long-acting active metabolites"
    ],
    "correct_option_index": 0,
    "blooms_level": "Apply",
    "naplex_domain": "Pharmacokinetics / Biotransformation",
    "acpe_outcomes": ["1.1", "2.1"],
    "difficulty_target_p": 0.6,
    "discrimination_target_d": 0.35,
    "topic_tags": ["BZDs", "SAR", "3OH", "Metabolism"],
    "distractor_rationale": {
      "1": "Reverses correct Phase II concept.",
      "2": "3-OH generally decreases lipophilicity.",
      "3": "Confuses with long-acting N-alkyl BZDs."
    }
  },
  {
    "id": "L01_Q5",
    "stem": "Which structural feature best explains the ultra-short duration of remimazolam compared with midazolam?",
    "options": [
      "Increased affinity for α2/α3 subunit–containing receptors",
      "Highly lipophilic N-alkyl side chain",
      "Lack of a 3-hydroxyl group on Ring B",
      "Ester-containing side chain rapidly hydrolyzed by esterases"
    ],
    "correct_option_index": 3,
    "blooms_level": "Analyze",
    "naplex_domain": "Drug Design / Advanced Pharmacology",
    "acpe_outcomes": ["1.1", "4.1"],
    "difficulty_target_p": 0.55,
    "discrimination_target_d": 0.35,
    "topic_tags": ["Remimazolam", "SoftDrug", "SAR"],
    "distractor_rationale": {
      "0": "Subunit preference does not explain ultra-short PK.",
      "1": "Would generally prolong duration.",
      "2": "Not the primary driver of ultra-short t1/2."
    }
  },
  {
    "id": "L01_Q6",
    "stem": "Stimulation of which GABAA α subunit is most closely associated with sedation and anterograde amnesia?",
    "options": [
      "α2",
      "α1",
      "α3",
      "α5"
    ],
    "correct_option_index": 1,
    "blooms_level": "Understand",
    "naplex_domain": "Pharmacology / Toxicology",
    "acpe_outcomes": ["1.1"],
    "difficulty_target_p": 0.7,
    "discrimination_target_d": 0.3,
    "topic_tags": ["BZDs", "ReceptorSubtype"],
    "distractor_rationale": {
      "0": "Associated more with anxiolysis.",
      "2": "Also more anxiolytic/muscle relaxant.",
      "3": "Cognitive effects but not primary sedative target."
    }
  },
  {
    "id": "L01_Q7",
    "stem": "A 70-year-old patient with cirrhosis requires a short course of therapy for insomnia. Which benzodiazepine is MOST appropriate from a metabolic standpoint?",
    "options": [
      "Flurazepam",
      "Diazepam",
      "Temazepam",
      "Quazepam"
    ],
    "correct_option_index": 2,
    "blooms_level": "Analyze",
    "naplex_domain": "Patient-Specific Therapy / Pharmacotherapy",
    "acpe_outcomes": ["2.1", "3.1"],
    "difficulty_target_p": 0.6,
    "discrimination_target_d": 0.35,
    "topic_tags": ["BZDs", "HepaticImpairment", "PK"],
    "distractor_rationale": {
      "0": "Long-acting with active metabolites.",
      "1": "Long-acting and Phase I–dependent.",
      "3": "Highly lipophilic with active metabolites and accumulation risk."
    }
  },
  {
    "id": "L01_Q8",
    "stem": "Which structural pattern is most associated with formation of long-acting active metabolites and clinical accumulation?",
    "options": [
      "3-hydroxyl group on Ring B",
      "Ester side chain designed for esterase hydrolysis",
      "Unsubstituted phenyl ring at C5",
      "N-alkyl side chain and high lipophilicity"
    ],
    "correct_option_index": 3,
    "blooms_level": "Analyze",
    "naplex_domain": "Pharmacokinetics / Biotransformation",
    "acpe_outcomes": ["1.1", "2.1"],
    "difficulty_target_p": 0.55,
    "discrimination_target_d": 0.35,
    "topic_tags": ["BZDs", "Metabolism", "ActiveMetabolites"],
    "distractor_rationale": {
      "0": "Associated with shorter duration via Phase II.",
      "1": "Characteristic of soft drugs with short t1/2.",
      "2": "Necessary for binding but not primary driver of accumulation."
    }
  },
  {
    "id": "L01_Q9",
    "stem": "Flumazenil reverses the effects of benzodiazepines primarily by:",
    "options": [
      "Enhancing GABA binding to the GABAA receptor",
      "Blocking the NMDA receptor channel",
      "Competitively antagonizing the benzodiazepine binding site on GABAA receptors",
      "Inhibiting benzodiazepine metabolism in the liver"
    ],
    "correct_option_index": 2,
    "blooms_level": "Understand",
    "naplex_domain": "Pharmacology / Toxicology (Antidotes)",
    "acpe_outcomes": ["1.1"],
    "difficulty_target_p": 0.75,
    "discrimination_target_d": 0.3,
    "topic_tags": ["Flumazenil", "Antidote"],
    "distractor_rationale": {
      "0": "Describes BZD action, not flumazenil.",
      "1": "Irrelevant receptor system.",
      "3": "Mechanism is receptor-level, not metabolic."
    }
  },
  {
    "id": "L01_Q10",
    "stem": "Chronic use of benzodiazepine sedative-hypnotics most commonly leads to which change in sleep architecture?",
    "options": [
      "Increased slow-wave (Stage 3–4) sleep and increased REM sleep",
      "Decreased slow-wave (Stage 3–4) sleep and decreased REM sleep",
      "Increased REM sleep and decreased Stage 2 sleep",
      "Decreased Stage 2 sleep and increased awakenings"
    ],
    "correct_option_index": 1,
    "blooms_level": "Understand",
    "naplex_domain": "Therapeutic Effects / Adverse Effects",
    "acpe_outcomes": ["1.1", "2.1"],
    "difficulty_target_p": 0.6,
    "discrimination_target_d": 0.3,
    "topic_tags": ["BZDs", "SleepArchitecture"],
    "distractor_rationale": {
      "0": "Opposite of typical BZD effect.",
      "2": "Misrepresents REM behavior under BZDs.",
      "3": "Contradicts decreased awakenings typically seen acutely."
    }
  }
]
